Dendreon Appoints Lindsay Rocco To Lead Corporate Communications

Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of Lindsay Rocco as executive vice president, corporate communications and member of the executive committee, effective immediately. In this role, Ms. Rocco will be responsible for all communications functions of the Company and will report directly to John H. Johnson, chairman, president and chief executive officer of Dendreon.

Ms. Rocco has extensive healthcare communications experience with large pharmaceutical companies as well as specialized public relations agencies. Most recently, she was senior vice president and a member of the leadership team at Rx Mosaic Health, a specialty healthcare public relations agency within the Omnicom Group. She helped to build and grow Rx Mosaic Health since its establishment six years ago, and served as a senior communications strategist for biotechnology and pharmaceutical clients within competitive and challenging therapeutic categories, including oncology, rheumatology and neurology.

“We are pleased to welcome Lindsay to Dendreon,” said John H. Johnson, chairman, president and chief executive officer of Dendreon. “Lindsay is a seasoned communicator with a deep understanding of the oncology space and a true passion for Dendreon’s mission to help advanced prostate cancer patients lead longer and better lives. Lindsay’s energy and expertise in healthcare communications makes her an ideal addition to our leadership team.”

Ms. Rocco added, “I am honored to join Dendreon at such an important time for the Company. I look forward to being a member of the executive committee and working together with the entire organization to help transform Dendreon from a pioneer to a leader in immunotherapy.”

Prior to joining Rx Mosaic Health, Ms. Rocco served as a director, public affairs at Roche-Genentech. Throughout her career, Ms. Rocco has also held senior-level positions with several healthcare public relations agencies within global holding companies, including the Omnicom Group and Publicis, and with MCS Healthcare Public Relations, an independent agency.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes